echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Lingbei antidepressants in crisis again? Yangzijiang and other 6 to grab the first imitation

    Lingbei antidepressants in crisis again? Yangzijiang and other 6 to grab the first imitation

    • Last Update: 2021-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical network November 16 days ago, CDE official website shows that stone pharmaceutical group Europharma's hydrobrominate voxitin tablet imitation 4 categories of listing applications were accepted.
    meters of intranet data show that in 2019, China's public medical institutions terminal voxel tablet sales of more than 30 million yuan, the first half of this year increased 190 percent year-on-year, only one production enterprises in Lingbei.
    Prior to this, Yangzijiang Pharmaceuticals, Zhengda Tianqing Pharmaceutical Group, Jiangsu Haussen Pharmaceuticals, Chengdu Bett Pharmaceuticals and other five enterprises have submitted applications for listing, in the review and approval (in the drug review center).
    data show that hydrobrominate vulcanization tablets are used to treat depression in adults.
    November 2017, the hydrobrominate vulcanization tablets (commodity name Da Yue) developed by the Danish company Lingbei were approved for listing by the State Drug Administration.
    In recent years, China's public medical institutions terminal vulcanization tablet sales (unit: 10,000 yuan) Source: China's public medical institutions terminal competition pattern Mienet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal voxelstatin tablet sales of more than 30 million yuan, the first half of this year increased by 190% year-on-year, production enterprises only Lingbei one.
    source: MED2.0 China Drug Review Database Prior to this, Yangzijiang Pharmaceuticals, Zhengda Tianqing Pharmaceutical Group, Jiangsu Haussen Pharmaceuticals, Chengdu Bett Pharmaceuticals and other 5 enterprises have submitted applications for listing, in the review and approval (in the drug review center).
    from the state start time, Yangzijiang pharmaceutical industry is the earliest.
    source: CDE official website, Mienet database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.